Thrombosis centres and AVKs monitoring in COVID-19 pandemic

Vitamin K-Antagonists (VKAs) are the treatment of choice in patients with indications other than atrial fibrillation and venous thromboembolism. Moreover, some patients still assume VKAs refusing to change their therapy when direct oral anticoagulants (DOACs) are properly indicated. The COVID-19 pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Barcellona, Doris, Marongiu, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
IM-Point of view
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369471/
https://www.ncbi.nlm.nih.gov/pubmed/32686059
http://dx.doi.org/10.1007/s11739-020-02439-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369471/
https://www.ncbi.nlm.nih.gov/pubmed/32686059
http://dx.doi.org/10.1007/s11739-020-02439-4

Ejemplares similares